AD-Detect™ Likelihood Score

For decades, the only way to know whether Alzheimer's was building in your brain was to wait for memory problems, then confirm it with a spinal tap or an expensive PET scan. The AD-Detect (Alzheimer's Disease Detect) Likelihood Score changes that equation. It uses a blood draw to estimate whether you are likely carrying the sticky protein plaques that define the disease, often years before any symptoms show up.

This is one of the first practical ways to look inside the brain's Alzheimer's biology without imaging. It does not diagnose Alzheimer's on its own, but it can tell you whether your number sits in a range that warrants closer attention, lifestyle action, and follow-up testing.

What This Score Actually Measures

The score is built from the Quest AD-Detect plasma test, which measures two related fragments of a brain protein called amyloid-beta (Aβ42 and Aβ40) and then calculates the ratio between them. A low ratio in the blood tends to mirror a high amount of amyloid plaque in the brain, which is the protein buildup that defines Alzheimer's disease. The likelihood score translates that ratio into a category of risk.

Studies using this assay have used a plasma ratio cutoff to flag people as likely amyloid-positive versus amyloid-negative. Some related blood-based risk models combine the ratio with APOE (Apolipoprotein E) genetic status and age and report three categories: higher-risk, lower-risk, and an intermediate band where roughly half of people have amyloid plaques visible on brain scans.

Alzheimer's Disease Risk

Amyloid plaque buildup is the earliest known biological signature of Alzheimer's disease, and it can begin a decade or more before memory symptoms appear. The plasma amyloid ratio underlying this score is one of the better-studied blood markers of that process.

In a study of adults across cognitively normal, mild cognitive impairment, and Alzheimer's dementia groups, the plasma Aβ42/40 ratio matched brain amyloid PET scans with strong overall accuracy. People with mild cognitive impairment who were amyloid-positive (low ratio) showed much higher rates of a specific memory error, called semantic intrusions, than people with mild cognitive impairment who were amyloid-negative, even after controlling for overall cognitive scores.

Across larger blood biomarker studies, low plasma amyloid ratios have been linked to higher risk of future cognitive decline and progression to dementia. Plasma amyloid ratios distinguish Alzheimer's dementia and amyloid-positive mild cognitive impairment from cognitively normal, amyloid-negative older adults with strong accuracy.

How It Compares to Other Alzheimer's Tests

You can think of this score as a screening layer, not a final diagnosis. Cerebrospinal fluid (CSF) testing and amyloid PET scans remain the most direct ways to confirm Alzheimer's biology, but both are invasive, expensive, or both. Blood-based tests like this one fill the gap by giving a probability you can act on without a needle in your spine or an hour in a scanner.

Among blood markers, the amyloid ratio is most useful for detecting plaque burden. Other newer markers such as phosphorylated tau (p-tau217) detect different parts of the disease process. In head-to-head comparisons, plasma models combining amyloid ratio, APOE status, and age have predicted CSF amyloid status with strong accuracy, while cognitive screens like the MMSE (Mini-Mental State Examination) score noticeably lower on the same task, so the blood biology adds real information beyond what a memory test alone can catch.

Why a Single Reading Is Not Enough

This is a newer category of test, and the blood biomarkers behind it can show meaningful short-term variation in the same person. One memory clinic study of plasma Alzheimer's biomarkers found low within-person short-term variation but moderate between-person variation, meaning your number needs to be tracked over time, not judged by one draw.

Kidney function also matters. Blood Alzheimer's biomarker concentrations are influenced by how well your kidneys clear proteins, and one analysis found that reduced kidney function can shift readings enough to alter their interpretation, though after adjusting for age and sex the impact on detecting amyloid positivity was smaller.

For a marker that estimates a slowly progressing brain process, the trajectory matters more than any single result. A reasonable approach: get a baseline now, retest in 6 to 12 months if your score sits in an intermediate or elevated range, and track at least every one to two years thereafter. If you are making major lifestyle changes aimed at brain health, retesting at 6 to 12 months gives the underlying biology time to shift in a measurable way.

When Results Can Be Misleading

This is a research-grade score with cutpoints that are still being refined, and several things can move the number without changing the underlying brain biology:

• Kidney function: reduced kidney clearance can change plasma biomarker levels independently of brain amyloid status, and may distort interpretation if your kidney function is impaired.
• Blood-brain barrier integrity: changes in the barrier that separates your blood from your brain can influence how much of these proteins reach your bloodstream.
• Recent stroke or major medical illness: one real-world cohort found that blood-based Alzheimer's biomarkers performed less reliably in people who had a recent stroke or a high burden of other medical conditions.
• Age and APOE genotype: these are not errors but built-in modifiers that affect where your number is expected to sit, which is why some blood-based scoring models adjust for them directly.

What an Unexpected Result Should Prompt You to Do

A low ratio or high likelihood score is not a diagnosis. It is a signal that warrants a closer look. If your result lands in an abnormal or intermediate range, the productive next steps are:

• Confirm with a repeat blood draw in a few months to rule out transient variation.
• Add complementary biomarkers such as plasma p-tau217, which targets a different part of the Alzheimer's process, or GFAP (Glial Fibrillary Acidic Protein), which reflects brain cell stress.
• Get a formal cognitive assessment if you have not already, even if you feel fine, since baseline scores are easier to interpret when paired with how you actually perform on standardized memory tasks.
• Consider referral to a memory or behavioral neurology specialist for confirmatory testing with CSF analysis or amyloid PET if multiple blood markers are abnormal.

For a younger person with strong family history or APOE ε4 genotype, an abnormal result is a reason to act on the modifiable side of brain aging now. For an older person with no symptoms, current expert guidance is that a single abnormal blood test is not enough to label you as having Alzheimer's, since some amyloid-positive older adults never develop symptoms.

How to Think About a Newer Test Like This

Blood-based Alzheimer's testing is a fast-moving field. Standardized cutpoints are still being refined, and major specialty guidelines currently support these tests mainly for people with cognitive symptoms being evaluated in specialist settings, not as a routine screen for healthy adults. That does not mean the information is worthless if you are without symptoms. It means your result should be treated as one input into a larger picture, not as a verdict.

Getting a baseline now, while you feel sharp, gives you a personal reference point for the future. As the science matures and cutpoints firm up, you will have a trajectory to compare against, not just a single number reported under whatever the cutoffs happen to be a decade from now.